Peptides for Myostatin Inhibition

2 research peptides are currently studied for myostatin inhibition. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Evidence Rating: C

Category: Muscle Growth / Monoclonal Antibody

Trevogrumab (REGN1033) is a fully human monoclonal antibody designed to selectively bind and neutralize myostatin (GDF-8), a protein that plays a critical role in inhibiting muscle growth. Developed by Regeneron Pharmaceuticals, Trevogrumab is currently undergoing Phase II-III clinical trials, notably in the context of sarcopenia and muscle wasting diseases. Its development signifies a shift towards targeted pharmaceutical interventions in myostatin inhibition, providing advantages such as high specificity and a longer half-life compared to traditional peptide-based therapies. The ongoing TOPAZ program is particularly noteworthy as it investigates Trevogrumab in combination with garetosmab, an anti-activin A antibody, for the treatment of inclusion body myositis. Preliminary findings suggest an increase in lean muscle mass, although comprehensive data on efficacy and safety are still pending as trials continue.

Key claims: Increases lean muscle mass; Treats inclusion body myositis.

Evidence Rating: D

Category: Muscle Growth

Myostatin propeptide, the N-terminal prodomain of myostatin (GDF-8), functions as an endogenous inhibitor of myostatin signaling. When myostatin is cleaved from its precursor, the propeptide remains associated with the mature myostatin domain, maintaining it in a latent state. Research indicates that exogenous administration of myostatin propeptide can effectively bind to and sequester active myostatin, thereby preventing its interaction with activin type IIB receptors (ActRIIB) on muscle cells. This mechanism of action has been associated with increased muscle hypertrophy in various preclinical models. Notably, natural mutations leading to myostatin loss of function in certain cattle breeds (e.g., Belgian Blue) and dog breeds (e.g., whippets) have been documented to cause significant muscle growth, reinforcing the potential of myostatin inhibition as a therapeutic strategy. However, the current evidence base for myostatin propeptide remains limited, primarily confined to preclinical studies.

Key claims: Increases muscle mass by inhibiting myostatin; Natural myostatin inhibition causes dramatic muscle growth.